HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gemdo Warning Letter Speaks Volumes About FDA Concerns, Industry Challenges

This article was originally published in The Rose Sheet

Executive Summary

There is much for cosmetic stakeholders to take away from FDA’s April 16 warning letter to Gemdo Cosmetics Inc., which highlights some key enforcement priorities at the agency and topline issues currently facing the industry as a whole.

You may also be interested in...

FDA Warns Gilchrist & Soames Following Massive Contamination Recall

G&S, which manufactures personal-care products for hotels and spas worldwide, recalled more than 2 million potentially contaminated units of bath and body products last year, but its regulatory compliance issues are not behind it yet. In a March 16 warning letter, FDA cites the firm for inspection failings and product sample analyses that render its products adulterated under US cosmetics law.

Cosmetic Recalls Dominated By Microbial Contamination

Infographic – An analysis by "The Rose Sheet" of FDA data from 2011-2015 finds bacterial or mold contamination to be the most frequently cited rationale for cosmetic recalls reported during the five-year period. Click the buttons in the interactive graphic below to view and compare data.

In Brief: U.S. Cosmetic-Related Bills Gain Congressional Support; More

Support grows for federal bills to ban cosmetic animal testing and use of synthetic plastic microbeads in the U.S. More news in brief.

Related Content

Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts